Scientific EXPERT Act of 2025
- Sponsor
- Rep. Matsui, Doris O. [D-CA-7]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Feb 24, 2025
Bottom line
The bill creates a structured, collaborative forum to accelerate drug development for rare diseases by fostering scientific alignment between external stakeholders and the FDA.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to establish a formal process for externally led, science-focused drug development meetings (EL-SFDD meetings). These meetings, to be convened by the Reagan-Udall Foundation for the FDA, will bring together medical experts, drug sponsors, scientific organizations, and patient groups to discuss scientific challenges and identify novel approaches for developing drugs for rare diseases and conditions. The bill mandates a minimum number of meetings annually and requires the FDA to publicly report on how input from these meetings is incorporated into drug approval processes and regulatory decision-making.
Proponents argue
Supporters argue that this bill will streamline the drug development process for rare diseases by facilitating early and structured scientific dialogue. They contend that bringing together diverse experts, including patient organizations, will help identify critical scientific challenges, align on innovative clinical trial designs, and leverage biomarkers more effectively, ultimately expediting the availability of treatments for unmet medical needs. This collaborative approach is seen as a way to enhance regulatory predictability and efficiency without compromising safety or efficacy standards.
Opponents contend
Critics might express concerns that adding more formal meeting processes could inadvertently create additional bureaucratic layers or divert FDA resources, potentially slowing down rather than accelerating drug approvals. Some may also argue that the existing mechanisms for stakeholder engagement are sufficient and that a new mandated process, even if externally led, might not significantly improve outcomes while adding to administrative overhead. There could also be concerns about potential influence from industry representatives in these externally led meetings.
The bill is concise and clearly written, making it accessible for a reader to understand its provisions and implications within a short timeframe.
Section 2, adding new Section 770A(a)
Establishment of Externally Led, Science-Focused Drug Development Meetings (EL-SFDD)
This provision directs the Secretary of Health and Human Services (acting through the FDA) to create and implement a process for EL-SFDD meetings. These meetings are designed to bring together various stakeholders, including medical experts, drug sponsors, scientific organizations, and patient organizations, to discuss scientific challenges and opportunities in developing drugs for rare diseases and conditions. The goal is to align on novel approaches for drug development, such as clinical trial designs, endpoints, and the use of biomarkers.
Supporters argue
Supporters argue this provision creates a vital, structured mechanism for collaborative problem-solving, which is particularly crucial for rare diseases where scientific pathways may be less defined. It ensures that the FDA benefits from external expertise and patient perspectives early in the development cycle, leading to more efficient and targeted research.
Critics contend
No specific opposition is typically raised against the concept of scientific collaboration. However, some might argue that existing FDA mechanisms for engagement are sufficient, and this new process could add unnecessary bureaucracy or strain resources without a clear demonstration of added value beyond current practices.
Tradeoffs
The provision balances the desire for increased external scientific input and collaboration with the need to maintain FDA's independent regulatory authority and manage its resources effectively. It aims to accelerate development without compromising the rigor of the review process.
Section 2, adding new Section 770A(b)
Arrangement with Reagan-Udall Foundation and Steering Committee
This provision mandates that the Secretary enter into an arrangement with the Reagan-Udall Foundation for the FDA to convene at least four EL-SFDD meetings annually, each focusing on different rare diseases. It also establishes a permanent Science-Focused Drug Development Multistakeholder Steering Committee within the Foundation. This committee will advise on implementation, establish a topic suggestion process, review suggestions, and recommend meeting topics based on criteria like unmet needs, patient population size, and potential for regulatory flexibility.
Section 2, adding new Section 770B(a) and (b)
Required Actions Following EL-SFDD Meetings: Incorporation of Input and Annual Report
This provision mandates two key actions after EL-SFDD meetings. First, when approving or licensing a drug, the Secretary must publicly state if a relevant EL-SFDD meeting was held and describe how its input was incorporated into the risk-benefit assessment. Second, the Secretary must submit an annual report to Congress summarizing the number and topics of meetings, FDA participation, workload impact, and how meeting input was used in drug development deliberations and regulatory decision-making.
This rule of construction explicitly states that nothing in the section shall be construed 'to increase the number of review cycles for drugs.'
Section 2, adding new Section 770A(d)(7)
Why it matters:This is standard legislative practice for clarifying the scope and intent of a new provision, ensuring it doesn't inadvertently create unintended consequences or conflict with existing regulatory processes.
Case for: Supporters would argue this clause is essential to reassure stakeholders, particularly drug sponsors, that the new meeting process is intended to streamline and accelerate drug development, not to add new hurdles or delays to the existing review timelines.
Case against: No specific case against this clarification, as it aims to prevent an undesirable outcome. However, critics might implicitly question whether the new process, even with this clause, could still indirectly lead to delays if not managed efficiently.
Estimated impact: Ensures that the new EL-SFDD meetings are integrated into the existing drug review framework without extending the formal review periods, maintaining predictability for drug developers.
This rule of construction clarifies that nothing in the section prohibits the Reagan-Udall Foundation from soliciting or accepting funds pursuant to section 770(i) for the purposes of planning or operating an EL-SFDD meeting.
Section 2, adding new Section 770A(f)(2)
Why it matters:This is a standard legislative practice to ensure that a new authorization of appropriations does not inadvertently restrict existing funding mechanisms or capabilities of an entity like the Reagan-Udall Foundation.
Case for: Proponents would argue this clause is important for the financial sustainability and flexibility of the EL-SFDD meeting process. It allows the Foundation to leverage its existing authority to secure additional funding, potentially beyond the direct federal appropriation, ensuring robust support for the meetings.
Case against: Critics might raise concerns about the potential for industry funding to influence the agenda or outcomes of the EL-SFDD meetings, even with conflict of interest policies in place. They might argue that relying on external funding sources could compromise the perceived neutrality of the process.
Estimated impact: Potentially increases the financial resources available for convening EL-SFDD meetings, allowing for more frequent or comprehensive discussions than federal appropriations alone might support.